News Releases
VBL Therapeutics to Present at the UBS Global Life Sciences Conference
September 13, 2011
VBL Therapeutics To Present Updated Clinical Results for VB-111 at 2011 ASCO Annual Meeting
May 23, 2011
VBL Therapeutics Presents Two Studies on Novel Anti-Angiogenic Vector at 102nd Annual AACR Meeting
March 31, 2011
VBL Announces Initiation of Two Clinical Trials for VB-111, Targeted, Dual-Action, Anti-Angiogenic, Vascular Disruptive Agent for Cancer
January 31, 2011
Data Published in Current Opinion in Lipidology Suggest Anti-Inflammatory Role for Oxidized Phospholipid Analogs, including VB-201, Lead VBL Compound
December 1, 2010
VBL Therapeutics to Present at the Fifth Annual JMP Securities Healthcare Conference
September 20, 2010
VBL Therapeutics to Present at the UBS Global Life Sciences Conference
September 15, 2010
Data Published in Journal of Neuroimmunology Suggest Anti-Inflammatory Role for Lead VBL Therapeutics Compound in CNS Inflammatory Diseases
September 14, 2010
VBL Presents Positive Preclinical Data on Immune Modulator in Rheumatoid Arthritis at EULAR Annual Meeting
June 17, 2010
VBL Therapeutics to Present Data on VB-201 for Rheumatoid Arthritis at EULAR Annual Meeting
June 10, 2010
VBL Therapeutics to Present Anti-Inflammatory Properties of VBL-201 at Keystone Symposium
June 1, 2010
VBL Therapeutics to Present Data from VB-201 and VB-111 at Prominent Cancer Research and Dermatology Medical Meetings
April 13, 2010
